Rödel F, Fleischmann M, Diefenhardt M, Dapper H, Hoffmann A, Rödel C, Martin D, Fokas E. Emerging advances and future opportunities in the molecular and therapeutic landscape of anal cancer. Nat Rev Clin Oncol 2025 (PMID: 40360682).
Author: Sabine Kapfhamer
(68)Ga-Labeled Fibroblast Activation Protein Inhibitor ((68)Ga-FAPI) PET for Pancreatic Adenocarcinoma: Data from the (68)Ga-FAPI PET Observational Trial
Kessler L, Hirmas N, Pabst KM, et al. (68)Ga-Labeled Fibroblast Activation Protein Inhibitor ((68)Ga-FAPI) PET for Pancreatic Adenocarcinoma: Data from the (68)Ga-FAPI PET Observational Trial (PMID: 37973185). J Nucl Med. 2023.
Differential activity of MAPK signalling defines fibroblast subtypes in pancreatic cancer
Veghini L, Pasini D, Fang R, et al. Differential activity of MAPK signalling defines fibroblast subtypes in pancreatic cancer (PMID: 39627211). Nat Commun. 2024.
1525P – Nab-paclitaxel/gemcitabine with or without epigenetic targeting followed by consolidating immune targeting with durvalumab and lenalidomide in patients with advanced pancreatic ductal adenocarcinoma: Results from the SEPION/AIO-PAK-0118 phase I/II study
Siveke J.T., Dorman K., Siegler G.M., Seufferlein T., Trojan J., Waldschmidt D.T., Koenig A.O., Schipp D., Liffers S.T., Kunzmann V. 1525P – Nab-paclitaxel/gemcitabine with or without epigenetic targeting followed by consolidating immune targeting with durvalumab and lenalidomide in patients with advanced pancreatic ductal adenocarcinoma: Results from the SEPION/AIO-PAK-0118 phase I/II study. Conference contribution (ESMO 2024).
Heterogeneity-driven phenotypic plasticity and treatment response in branched-organoid models of pancreatic ductal adenocarcinoma
Papargyriou A, Najajreh M, Cook DP, et al. Heterogeneity-driven phenotypic plasticity and treatment response in branched-organoid models of pancreatic ductal adenocarcinoma (PMID: 39658630). Nat Biomed Eng. 2024.
Molecular adaptation to neoadjuvant immunotherapy in triple-negative breast cancer (GeparNuevo)
Denkert C, Schneeweiss A, Rey J, et al. Molecular adaptation to neoadjuvant immunotherapy in triple-negative breast cancer (GeparNuevo) (PMID: 39566464). Cell Rep Med. 2024.
Small extracellular vesicles and particles (sEVPs) derived from tumor-free pre-metastatic organs promote breast cancer metastasis and support organotropism
Cheytan T, Schneider M, Wurth R, et al. Small extracellular vesicles and particles (sEVPs) derived from tumor-free pre-metastatic organs promote breast cancer metastasis and support organotropism (PMID: 40057730). Mol Cancer. 2025.
IL-17RA signaling provides dual tumor-suppressor function during late-stage colorectal carcinogenesis
Denk D, Ramakrishnan M, Conche C, et al. IL-17RA signaling provides dual tumor-suppressor function during late-stage colorectal carcinogenesis (PMID: 40023157). Immunity. 2025.
Dynamics of molecular heterogeneity in high-risk luminal breast cancer-From intrinsic to adaptive subtyping (PenelopeB)
Denkert C, Rachakonda S, Karn T, et al. Dynamics of molecular heterogeneity in high-risk luminal breast cancer-From intrinsic to adaptive subtyping (PenelopeB) (PMID: 39933898). Cancer Cell. 2025.
Study protocol of the METAPANC trial – intensified treatment in patients with local operable but oligometastatic pancreatic cancer – multimodal surgical treatment versus chemotherapy alone: a randomized controlled trial
Ghadimi M, Pelzer U, Besselink MG, et al. Study protocol of the METAPANC trial – intensified treatment in patients with local operable but oligometastatic pancreatic cancer – multimodal surgical treatment versus chemotherapy alone: a randomized controlled trial (PMID: 39915735). BMC Cancer. 2025.
